Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Free Cash Flow: 2020-2025

Historic Free Cash Flow for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$46.4 million.

  • 4D Molecular Therapeutics' Free Cash Flow fell 48.89% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.1 million, marking a year-over-year decrease of 58.49%. This contributed to the annual value of -$138.4 million for FY2024, which is 76.13% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Free Cash Flow stood at -$46.4 million for Q3 2025, which was down 6.82% from -$43.4 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Free Cash Flow high stood at -$1.6 million for Q3 2023, and its period low was -$48.4 million during Q1 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' median Free Cash Flow value was -$30.6 million (recorded in 2024), while the average stood at -$32.3 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Free Cash Flow spiked by 93.14% in 2023, and later slumped by 1,877.73% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Free Cash Flow (Quarterly) stood at -$26.9 million in 2021, then increased by 13.46% to -$23.3 million in 2022, then fell by 8.12% to -$25.2 million in 2023, then plummeted by 85.77% to -$46.8 million in 2024, then crashed by 48.89% to -$46.4 million in 2025.
  • Its last three reported values are -$46.4 million in Q3 2025, -$43.4 million for Q2 2025, and -$48.4 million during Q1 2025.